1 ne, and the phosphodiesterase III inhibitor, amrinone.

2                 In vivo in dogs, intravenous amrinone 2 mg/kg plus infusion at 20 microg x kg(1) x mi

3 atelets in suspension were preincubated with amrinone 2.5 to 15 microg/mL; stimulated with the agonis

4                                              Amrinone also inhibited upregulation of ICAM-1 (p < .001

5 elevant concentrations of inotropes, such as amrinone and dopamine, which increase cAMP, could inhibi

6                                         Both amrinone and milrinone have significant effects on cardi

7 amined the effects of 2 commonly used PDEIs, amrinone and milrinone, on cardiac cell inflammatory res

8                            Pretreatment with amrinone, and to a lesser degree, with dopamine, at clin

9 xpression, all were significantly reduced by amrinone, beginning at concentrations of 10 to 50 micro

10   Results showed that at the cellular level, amrinone inhibited agonist-induced Ca2+ mobilization and

11                                The fact that amrinone inhibited human platelet activation at the cell

12 pinephrine (0.1 to 100 ng/mL) for 15 mins or amrinone lactate (0.25 to 10 microg/mL) for 20 mins.

13         Phosphodiesterase inhibitors such as amrinone may be found to exert significant inotropic eff

14 pretreated with increasing concentrations of amrinone or dopamine, or left untreated as controls, fol

15 nce of clinically relevant concentrations of amrinone or milrinone.

16    In contrast, increasing concentrations of amrinone produced increased peak augmentation of contrac

17                                     Overall, amrinone reduces activation of the key transcription fac

18                            Pretreatment with amrinone significantly decreased endothelial E-selectin

19 this increase was not reflected by increased amrinone-stimulated generation of cyclic AMP relative to

20 ad no effect, indicating that the effects of amrinone were not due to phosphodiesterase inhibition.

21 e have previously found that vesnarinone and amrinone, when given before LPS, prevented cytokine prod

22 nonadrenergic inotropic and vasodilator drug amrinone, which elevates platelet cAMP levels, would bot